Monoclonal Antibody Therapy in Treating Patients With Colorectal Cancer

NCT00005616 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2013-06-19

No results posted yet for this study

Summary

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.

PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients who have colorectal cancer.

Conditions

Interventions

PROCEDURE

conventional surgery

PROCEDURE

neoadjuvant therapy

PROCEDURE

radionuclide imaging

RADIATION

iodine I 131 monoclonal antibody F19

Sponsors & Collaborators

Principal Investigators

  • Sydney Welt, MD · Memorial Sloan Kettering Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-09-30
Primary Completion
2000-08-31
Completion
2000-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00005616 on ClinicalTrials.gov